An unknown individual and others acquired 3.2% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for KRW 2.9 billion.
April 19, 2018
Share
An unknown individual and others acquired 3.2% stake in SunBio,Inc. (XKON:A067370) from Kangpyung Telecom Co., Ltd. for KRW 2.9 billion on April 13, 2018. Kangpyung Telecom Co., Ltd sold 0.24 million shares of SunBio at KRW 12000 per share. After the deal, Kangpyung Telecom will retain 4.97% stake in SunBio,Inc.
An unknown individual and others completed the acquisition of 3.2% stake in SunBio,Inc. (XKON:A067370) from Kangpyung Telecom Co., Ltd. on April 13, 2018.
SunBio,Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. The Company operates its business through three segments. The Polyethylene Glycol (PEG) Derivative Product business segment is involved in the manufacturing and sale of PEG derivative products. The PEG derivatives are intermediate materials used in dermal filler, drug delivery systems, hydrogel, and nanotechnology. The Biosimilar Business segment is involved in the manufacturing and sale of royalty and technology transfer products. The main products are neutropenia treatment products, and hepatitis C treatment products. The New Drug Development Business segment is involved in the development of oxygen carriers, artificial blood, stroke aid agents, cartilage synovial fillers, dry mouth treatment drugs, and long-term preservatives.
SUNBIO,INC. 
